Safety of biologics in inflammatory bowel disease patients with COVID-19

BACKGROUND: Patients with Inflammatory bowel disease (IBD) remain highly concerned that either their disease or medications—namely, biologics—may increase the risk of severe coronavirus-2019 (COVID-19). We aimed to assess the safety of biologics in Inflammatory bowel disease (IBD) patients with COVI...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Yayımlandı:Int J Colorectal Dis
Asıl Yazarlar: Weissman, Simcha, Aziz, Muhammad, Smith, Wade-Lee, Elias, Sameh, Swaminath, Arun, Feuerstein, Joseph D.
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Springer Berlin Heidelberg 2021
Konular:
Short Communication
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC8205311/
https://ncbi.nlm.nih.gov/pubmed/34131784
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00384-021-03977-9
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller